OCUGEN OCGN 深 沪
等待开盘 11-12 09:30:00 美东时间
0.9604
+0.010
+1.09%
华盛通- 最 高1.01
- 今 开1.01
- 成交量 504.81万股
- 最 低 0.9112
- 昨 收 0.95
- 总市值 3.26亿
- 52周最高 2.725
- 市盈率 静 --
- 换手率 1.49%
- 52周最低 0.6909
- 委 比 52.48%
- 总股本 3.39亿
- 历史最高 18.77
- 量 比 0.63
- 振 幅 10.40%
- 历史最低 0.17
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ocugen Enters License Agreement for OCU400 in Asia-Pacific
Ocugen ( ($OCGN) ) has shared an announcement. On November 10, 2026, Ocugen ent...
11-10 21:59
Ocugen shares are trading higher after the company reported better-than-expected Q3 sales results.
Ocugen shares are trading higher after the company reported better-than-expected Q3 sales results.
11-05 02:54
UPDATE: Ocugen Q3 Adj. EPS $(0.06), Inline, Sales $1.951M Beat $1.098M Estimate
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $1.951 million which beat the analyst consensus esti...
11-04 23:21
Ocugen Q3 2026 Earnings Call Transcript
Ocugen (NASDAQ:OCGN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn mor...
11-04 22:34
Ocugen to Participate in Upcoming November Investor and Industry Conferences
Ocugen, Inc. announced it will present its innovative modifier gene therapy platform at two upcoming conferences in November 2026. Dr. Shankar Musunuri, Ocugen's Chairman, CEO, and Co-Founder, will speak at the Stifel 2026 Healthcare Conference in New York on November 12 and participate in a panel discussion at Cell & Gene Leaders Live 2026 in London on November 15. The Stifel presentation will be available via webcast on Ocugen's investor websit...
10-29 11:02
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
Ocugen, Inc. will host a conference call and live webcast on November 4, 2026, at 8:30 a.m. ET to discuss third quarter 2026 financial results and provide a business update. The event will be accessible via the Ocugen investor website or by phone using the provided dial-in numbers and access code. A replay will be available post-event. Ocugen is a biotech company developing gene therapies for blindness, targeting conditions like retinitis pigment...
10-22 11:00
Ocugen Highlights Progress in Ophthalmic Gene Therapy Pipeline
The latest update is out from Ocugen ( ($OCGN) ). On October 15, 2026, Ocugen r...
10-15 20:29
Ocugen Executes Licensing Agreement With Roots Pharma And Its Strategic Partner Al-Dhow International For Exclusive Rights To OCU400 For Treatment Of Retinitis Pigmentosa In Middle East And North Africa Region
Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapies Expands access to a potential one-time gene therapy for retinitis pigmentosa in a region with high disease prevalen...
10-14 18:32
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Ocugen, Inc. has signed a licensing agreement with Roots Pharmaceutical and Al-Dhow International Holding for exclusive rights to OCU400, a gene therapy for retinitis pigmentosa (RP), in the Middle East and North Africa (MENA) region. The agreement includes an upfront license fee, up to $4 million in initial development payments, potential sales milestones of $255 million, and 22% royalties. Ocugen will manufacture and supply OCU400. RP is a lead...
10-14 10:30
Transcript: Ocugen Q2 2026 Earnings Conference Call
Ocugen (NASDAQ:OCGN) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. View the webcast at https://e...
10-06 16:29
